ARF-BP1 as a potential therapeutic target.

British Journal of Cancer
D ChenW Gu

Abstract

In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9). ARF-BP1, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BP1 stabilised p53 and induced apoptosis. Notably, inactivation of ARF-BP1 also caused cell growth repression in p53-null cells and breast cancer cells with mutant p53. Thus, ARF-BP1 emerges as a novel therapeutic target against cancer regardless of p53 status.

References

Nov 13, 1999·Nature Cell Biology·J D WeberD Bar-Sagi
Sep 20, 2000·Genes & Development·J D WeberG P Zambetti
Mar 29, 2001·Proceedings of the National Academy of Sciences of the United States of America·F MartelliS R Grossman
May 2, 2001·Nature Cell Biology·S LlanosG Peters
Dec 12, 2001·Molecular and Cellular Biology·Chandrashekhar KorgaonkarDawn E Quelle
Jan 1, 2003·Seminars in Cancer Biology·Dan Michael, Moshe Oren
Mar 22, 2003·Current Opinion in Cell Biology·Christopher L Brooks, Wei Gu
Mar 26, 2003·Cell·Roger P LengSamuel Benchimol
Apr 30, 2003·Cell Death and Differentiation·M Oren
Dec 3, 2003·Annals of Medicine·Vladimir J N Bykov, Klas G Wiman
Jan 6, 2004·Science·Lyubomir T VassilevEmily A Liu
Jan 20, 2004·Molecular and Cellular Biology·David BertwistleCharles J Sherr
Jan 28, 2004·Cell·Charles J Sherr
Apr 23, 2004·Nature·David DornanVishva M Dixit
Jul 29, 2004·Cancer Biology & Therapy·Chad A CorcoranM Saeed Sheikh
Nov 30, 2004·Biochemical and Biophysical Research Communications·Sun Young YoonJae Wha Kim
Dec 8, 2004·The Journal of Biological Chemistry·Guillaume NormandPeter T Daniel
Mar 16, 2005·Molecular and Cellular Biology·Zhiqian LiuSimon S Wing
Apr 20, 2005·Oncogene·Sandra L Harris, Arnold J Levine
May 4, 2005·Biochemical and Biophysical Research Communications·T Soussi, G Lozano
Jul 2, 2005·Cell·Ayelet Shmueli, Moshe Oren
Oct 11, 2005·FEBS Letters·Matthew R WarrGordon C Shore

❮ Previous
Next ❯

Citations

Dec 6, 2007·BMC Biochemistry·Martin Scheffner, Olivier Staub
Jul 4, 2012·International Journal of Molecular Sciences·Chen-Feng QiHerbert C Morse
Jul 16, 2014·Molecular and Cellular Biology·Eun Ryoung JangEmilia Galperin
Jul 6, 2011·FEBS Letters·Svetlana V Khoronenkova, Grigory L Dianov
Nov 19, 2013·FEBS Letters·Wei Zhang, Sachdev S Sidhu
Mar 5, 2008·Journal of Cellular Physiology·Monica CattaneoIda Biunno
Nov 18, 2009·The Journal of Pathology·Monica Hollstein, Pierre Hainaut
Mar 24, 2011·Future Medicinal Chemistry·Akash Gunjan, Rakesh Kumar Singh
Apr 28, 2011·The EMBO Journal·Xinna ZhangXiongbin Lu
May 6, 2016·EMBO Reports·Katherine N ChoeGeorge-Lucian Moldovan
Apr 1, 2015·Molecular & Cellular Oncology·Florine ObristLorenzo Galluzzi
Sep 1, 2020·The FEBS Journal·Nicole LeBlancWei Zhang
May 29, 2019·Cell Biology International·Jun ImaiTakahiro Sakai
Jul 17, 2020·Cancer Cell International·Yizhi WangJunchao Guo
Sep 23, 2014·Oncotarget·Vivien LandréGerry Melino
Oct 8, 2009·Molecular Cancer Therapeutics·Tohru YamadaTapas K Das Gupta

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
co-immunoprecipitations

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.